Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 3
2018 2
2020 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter.
Turaj AH, Dahal LN, Beers SA, Cragg MS, Lim SH. Turaj AH, et al. Cancer Res. 2017 Jun 15;77(12):3376-3378. doi: 10.1158/0008-5472.CAN-17-0412. Epub 2017 Jun 5. Cancer Res. 2017. PMID: 28584185 No abstract available.
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.
Lim SH, Stuart B, Joseph-Pietras D, Johnson M, Campbell N, Kelly A, Jeffrey D, Turaj AH, Rolfvondenbaumen K, Galloway C, Wynn T, Coleman AR, Ward B, Long K, Coleman H, Mundy C, Bates AT, Ayres D, Lown R, Falconer J, Brake O, Batchelor J, Willimott V, Bowzyk Al-Naeeb A, Robinson L, O'Callaghan A, Collins GP, Menne T, Faust SN, Fox CP, Ahearne M, Johnson PWM, Davies AJ, Goldblatt D. Lim SH, et al. Among authors: turaj ah. Nat Cancer. 2022 May;3(5):552-564. doi: 10.1038/s43018-022-00364-3. Epub 2022 Mar 24. Nat Cancer. 2022. PMID: 35332334 Free PMC article.
Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment.
Turaj AH, Hussain K, Cox KL, Rose-Zerilli MJJ, Testa J, Dahal LN, Chan HTC, James S, Field VL, Carter MJ, Kim HJ, West JJ, Thomas LJ, He LZ, Keler T, Johnson PWM, Al-Shamkhani A, Thirdborough SM, Beers SA, Cragg MS, Glennie MJ, Lim SH. Turaj AH, et al. Cancer Cell. 2017 Dec 11;32(6):777-791.e6. doi: 10.1016/j.ccell.2017.11.001. Epub 2017 Nov 30. Cancer Cell. 2017. PMID: 29198913 Free PMC article.
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
Palazzo A, Herter S, Grosmaire L, Jones R, Frey CR, Limani F, Bacac M, Umana P, Oldham RJ, Marshall MJE, Cox KL, Turaj AH, Cragg MS, Klein C, Carter MJ, Tannheimer S. Palazzo A, et al. Among authors: turaj ah. J Immunol. 2018 Apr 1;200(7):2304-2312. doi: 10.4049/jimmunol.1700323. Epub 2018 Feb 16. J Immunol. 2018. PMID: 29453281 Free PMC article.